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Abstract
Mutations in the nuclear gene POLG (encoding the catalytic subunit of DNA polymerase
gamma) are an important cause of mitochondrial disease. The most common POLGmuta-
tion, A467T, appears to exhibit considerable phenotypic heterogeneity. The mechanism by
which this single genetic defect results in such clinical diversity remains unclear. In this
study we evaluate the clinical, neuropathological and mitochondrial genetic features of four
unrelated patients with homozygous A467T mutations. One patient presented with the
severe and lethal Alpers-Huttenlocher syndrome, which was confirmed on neuropathology,
and was found to have a depletion of mitochondrial DNA (mtDNA). Of the remaining three
patients, one presented with mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes (MELAS), one with a phenotype in the Myoclonic Epilepsy, Myopathy and
Sensory Ataxia (MEMSA) spectrum and one with Sensory Ataxic Neuropathy, Dysarthria
and Ophthalmoplegia (SANDO). All three had secondary accumulation of multiple mtDNA
deletions. Complete sequence analysis of muscle mtDNA using the MitoChip resequencing
chip in all four cases demonstrated significant variation in mtDNA, including a pathogenic
MT-ND5mutation in one patient. These data highlight the variable and overlapping clinical
and neuropathological phenotypes and downstreammolecular defects caused by the
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A467T mutation, which may result from factors such as the mtDNA genetic background,
nuclear genetic modifiers and environmental stressors.
Introduction
Mutations in the nuclear gene POLG, which encodes the catalytic subunit of DNA polymerase γ
(Pol γ), the sole enzyme responsible for DNA replication and repair in mitochondria, result in a
highly heterogeneous group of mitochondrial disorders [1]. The phenotypic spectrum of POLG-
related mitochondrial disease includes progressive external ophthalmoplegia (PEO), sensory
and cerebellar ataxia, encephalopathy, neuropathy, focal and generalised epilepsy, dysarthria,
distal myopathy, Parkinsonism, liver disease and premature ovarian failure [2–10]. Although
several distinct phenotypes have been reported in association with POLGmutations including
childhood-onset Alpers-Huttenlocher syndrome, autosomal recessive and dominant of forms of
PEO, myoclonic epilepsy, myopathy and sensory ataxia (MEMSA) and the ataxia-neuropathy
spectrum (ANS) disorders, current thinking suggests that these previously defined syndromes
are not discrete clinical entities but rather overlap considerably and lie on a continuum. One of
the major challenges ahead is to delineate the full spectrum of POLG-related disease.
The c.1399G>Amutation in exon 7 of POLG produces an alanine to threonine substitution
(A467T) at a highly conserved site and is the most frequent pathogenic mutation in POLG-related
mitochondrial disease. Exon 7 encodes the spacer domain of the polymerase, the function of
which is largely unknown; although mutagenesis of this conserved region in the fruit fly protein
has been shown to alter the activity, processivity and DNA-binding affinity of the enzyme [11].
A467T exhibits common European ancestry with a carrier frequency of approx. 0.2% to 0.3% in
mixed populations of European origin (http://exac.broadinstitute.org; http://evs.gs.washington.
edu/EVS) although the carrier frequency has been reported to be as high as 1.3% to 1.4% in Belgian
and British populations respectively [3, 12]. Assuming Hardy-Weinberg equilibrium, the predicted
homozygote rate would be 1 in 500,000 to 1 in 1,000,000 for a carrier frequency of 0.2% to 0.3%.
The A467Tmutation is functionally recessive and is usually found in trans with another POLG
mutation, although homozygous A467T mutations do occur (Human DNA Polymerase Gamma
Mutation Database, http://tools.niehs.nih.gov/polg/). In vitro studies have revealed that the A467T
mutant enzyme exhibits a profound reduction in polymerase activity and processivity as a result of
impaired interaction with the accessory subunit of the enzyme encoded by POLG2 [11, 13].
The reasons underlying the variability in clinical spectrum and phenotypic severity associ-
ated with the homozygous A467T substitution remain unclear. We studied four unrelated
patients with homozygous A467T POLGmutations and assessed them longitudinally to char-
acterise the clinical spectrum of A467T-related disease. We undertook molecular genetic stud-
ies including MitoChip resequencing analysis, to consider the role of genetic modifiers on
phenotype, and performed detailed pathological analysis of muscle, brain and liver samples.
We present the results of our investigations and consider the mechanisms by which homozy-
gous A467T mutations give rise to such diverse phenotypes.
Patients and Methods
Case histories
We investigated four patients of European descent with homozygous A467T POLG-related
mitochondrial disease. Clinical details are summarised in Table 1 and in the clinical vignettes
presented below.
A467T POLG-Related Mitochondrial Disease
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Patient 1: Alpers-Huttenlocher syndrome. Patient 1 was the second child of healthy
unrelated parents and was born at full term. Speech and motor delay were noted at the age of
two years. At three years she developed epilepsy and six months later experienced migrainous
attacks associated with vomiting, vertigo and transient left-sided weakness. Both electroen-
cephalogram (EEG) and electromyogram (EMG) were normal. At the age of four years she suf-
fered a 10-day episode of headache and vomiting culminating in seizures and coma. Computed
tomography (CT) of the brain was normal and EEG showed post-ictal changes only. At the age
of five years she developed status epilepticus. An EEG revealed bilateral post-ictal activity with
slow wave activity in the left hemisphere. A CT brain demonstrated mild cerebral oedema and
magnetic resonance imaging (MRI) brain appearances suggested chronic ischaemia of the grey
matter. A month later she was noted to have nystagmus, hypotonia of the lower limbs and
absent knee jerks. Liver function derangement was noted (Table 1). A clinical diagnosis of
Alpers-Huttenlocher syndrome was made. Her seizure disorder continued to worsen and she
died at the age of five years and six months. Post-mortem brain and liver histology subse-
quently confirmed the diagnosis of Alpers-Huttenlocher syndrome (see results below).
Patient 2: “MEMSA +”. Patient 2 was born at full term and had normal development
until the age of 6 years when she presented with an encephalopathic illness consisting of
Table 1. Summaries of the case histories of the four patients.
Patient 1 Patient 2 Patient 3 Patient 4
Age at presentation
(years)
3 6 20 24
Age at death
(years)
5.5 Alive at 16 44 Alive at 31
Symptoms at
presentation
Seizures Encephalitis-type presentation Diplopia Seizures
Clinical phenotype Alpers-Huttenlocher MEMSA+ SANDO “MELAS-like”
Blood/CSF results GGT 170 IU/l (reference <20
IU/L), AST 490 IU/L (reference
range 5 to 45 IU/l)
"lactate 2.6mmol/L (<2) Liver
function normal; "Plasma alanine
537 mcmol/L (150–450); #Plasma
arginine 28 mcmol/L (40–120);
CSF lactate 1.6mmol/L (<2); "CSF
protein 1.32 g/L (0.15–0.6); CSF
5MTHF 29 (46–120)
" lactate 2.3mmol/L
(< 1.65); CK 329
Normal lactate; Normal CSF
exam
Neurophysiology - EEG: Intermittent runs of rhythmic
delta activity; CS: sensory
neuropathy affecting legs
NCS: Severe axonal
neuropathy
NCS: Moderately severe
axonal sensory motor
neuropathy
Radiology Chronic grey matter ischaemia MRI: Bilateral occipital lesions
around calcarine sulci
- MRI: Right occipital infarct
Neuropathology Cortical degeneration in the
occipital and parietal lobes,
typical of PNDC. Bilateral
hippocampal sclerosis. Hepatic
microsteatosis
Brain biopsy: Non-speciﬁc; Muscle
histology: COX-negative ﬁbres
Muscle histology: " no.
of ragged red ﬁbres
and > 10 COX-negative
ﬁbres
Muscle histology: Ragged red
ﬁbres and COX-negative ﬁbres
and marked variation in ﬁbre
size with scattered groups of
atrophic ﬁbres.
Muscle Respiratory
Chain enzymes
- Complex I 0.126 (0.104–0.268);
Complex II 0.159 (0.040–0.204);
Complex IV 0.026 (0.014–0.034)
Complex I 0.170 (0.104–
0.268); Complex II 0.077
(0.040–0.204); Complex
IV 0.024 (0.014–0.034)
-
Key: 5MTHF, 5-methyltetrahydrofolate; AST, aspartate aminotransferase; COX, cytochrome oxidase; EEG, electroencephalogram; GGT, gamma-
glutamyltranspeptidase; MELAS, mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes; MEMSA, myoclonic epilepsy, myopathy, sensory
ataxia; NCS, nerve conduction studies; PNDC, progressive neuronal degeneration of childhood; SANDO, Sensory Ataxia Neuropathy Dysarthria
Ophthalmoplegia.
doi:10.1371/journal.pone.0145500.t001
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impaired consciousness, vomiting and generalised tonic-clonic seizures. One week later she
developed a left homonymous hemianopia. MRI brain demonstrated an enhancing lesion in
the right occipital lobe and an EEG demonstrated frequent occipital lobe discharges. A repeat
MRI showed persistence of the right-sided lesion, with additional left sided occipital lobe swell-
ing. A brain biopsy performed 9 weeks into admission revealed non-specific findings, with no
evidence of inflammation, vasculitis, malformation or metabolic disorder. She remained stable
until the age of 13 years when she developed stimulus sensitive myoclonus, tremor and a pro-
gressive cerebellar ataxia. She has remained cognitively intact throughout. Further investiga-
tions at the age of 15 years revealed mildly elevated blood lactate and alanine levels and a
sensory axonal peripheral neuropathy (Table 1). An MRI brain revealed bilateral occipital lobe
infarcts. Muscle biopsy demonstrated cytochrome-c oxidase (COX) negative fibres (see results
below) and lipid deposition. Spectrophotometric analysis of respiratory chain enzymes showed
low-normal complex I activity. Examination aged 17 years revealed gaze-evoked nystagmus.
Her vision was reduced to finger counting on the left and hand movements on the right. Fun-
doscopy demonstrated bilateral optic atrophy. In addition, she exhibited a hand tremor, stimu-
lus-sensitive myoclonus, head titubation, and gait ataxia. Motor strength was normal, reflexes
were present and symmetrical and plantar responses were flexor.
Patient 3: SANDO. Patient 3 presented at the age of 20 years with diplopia and bilateral
ptosis. Over the next five years he developed dysphagia, slurred speech and an unsteady gait. In
his twenties he experienced a tingling sensation in his hands and feet, which in his thirties pro-
gressed to involve his legs, trunk and arms. His mother and maternal uncle were also noted to
have ‘droopy eyelids’. Neurological examination at the age of 44 years demonstrated bilateral
ptosis and limitation of eye movements in all directions of gaze. His speech was dysarthric.
Tone and power were normal in all muscle groups. Sensory testing revealed a reduction in pin-
prick, light touch and temperature sensation in his hands and below the mid-shin level bilater-
ally. Romberg’s test was positive. His gait was broad-based and ataxic. Nerve conduction
studies revealed an axonal, primarily sensory peripheral neuropathy. Muscle histology demon-
strated several ragged red fibres and more than 10 COX-negative fibres (see results below). His
clinical presentation was consistent with a diagnosis of SANDO.
Patient 4: “MELAS-like”. Patient 4 presented at the age of 24 years with recurrent gen-
eralised seizures. At the time, she complained of an occipital headache and was noted to be
drowsy and confused. She subsequently developed left-sided weakness with sensory loss, and
examination also revealed a left homonymous hemianopia suggestive of a stroke-like episode.
An MRI brain scan demonstrated a right occipital infarct. A few months later, she was noted
to have increased jerking movements of her left arm suggestive of epilepsia partialis continua
with dystonia, which was refractory to treatment. Transpial resection brain surgery was
unsuccessful. She developed an asymptomatic axonal neuropathy, deafness and myopathic
weakness. The salient features on examination were: bilateral ptosis, ophthalmoparesis, a
dense left homonymous hemianopia, dysarthric speech, increased tone with clawing of the
left hand, and distal muscle weakness. In addition, Romberg’s test was positive and she
walked with a wide-based gait. Nerve conduction studies confirmed the presence of a moder-
ately severe axonal sensory motor neuropathy and a muscle biopsy demonstrated the typical
findings of a mitochondrial myopathy with ragged red fibres and COX-negative fibres (see
results below).
Neuropathology
Samples of formalin-fixed paraffin embedded (brain, liver) and fresh frozen (muscle, liver) tis-
sues were examined by standard diagnostic protocols.
A467T POLG-Related Mitochondrial Disease
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Biochemical analysis
Spectrophotometric assays of respiratory chain enzyme complexes were performed in homoge-
nised snap-frozen skeletal muscle biopsy specimens using standard methods [14].
Molecular genetics
Total genomic DNA was extracted from blood and muscle biopsy specimens from all four
patients using standard protocols. Testing for the A467T mutation was achieved by amplifica-
tion of exon seven of the POLG gene using flanking exonic primers followed by automated
Sanger sequencing of DNA extracted from peripheral blood leukocytes. MtDNA was assessed
for large-scale rearrangements and depletion using long range PCR and Southern blot analysis
of total genomic DNA from muscle. The entire mtDNA sequence was analysed in muscle
using the GeneChip1Human Mitochondrial Resequencing Array 2.0 (Affymetrix) according
to previously published methods [15]. The ~16.6 kb mitochondrial genome was amplified in
two fragments using the Expand Template Long PCR Kit from Roche Diagnostics (Mannheim,
Germany) according to the manufacturer's protocol. PCR primers and cycling conditions are
available on request. Concentration of DNA in the long PCR products was determined using
nanodrop spectrophotometry, and equimolar concentrations of the two PCR products were
pooled. These were digested with DNAseI. Prehybridisation, hybridisation, washing and scan-
ning of the GeneChip1 were performed according to the Affymetrix CustomSeq Resequencing
protocol. Sequences were analysed using GSEQ 4.2 software. SNPs were automatically called
by GSEQ and presented in a SNP viewer format. Haplogroups were assigned using MitoTool
software (http://www.mitotool.org/) by examination of key defining polymorphisms.
The study was approved and performed under the ethical guidelines issued by the Joint
National Hospital for Neurology and Neurosurgery and University College London—Institute
of Neurology Ethics Committee for clinical studies, with written informed consent obtained
for all subjects for genetic studies, diagnostic tests and medical procedures. In the case of
minors, informed written consent was obtained from their guardian on their behalf. All per-
sons providing consent were clinically assessed to have capacity.
Results
Pathology
Patient 1. The liver showed patchy, predominantly perivenular areas of enlarged finely
vacuolated hepatocytes and some congestion. On Oil red O staining, there was marked diffuse
increase in lipid deposition in a microsteatotic pattern (Fig 1a and 1b).
The fixed weight of the post-mortem brain was 1130 g. The external examination was unre-
markable. On coronal slicing, there were no significant abnormalities. In particular there was
no macroscopic evidence of focal cortical lesions. On histology (Fig 1c–1f), there were focal
areas of cortical damage, most prominent in the occipital lobes but also extending in to the
parietal lobes. The most severe foci (the occipital lobe) were characterized by neuronal loss,
vacuolation of the neuropil (imparting a reticulated appearance) and astrocytosis (confirmed
on GFAP (glial fibrillary acidic protein) staining). The more mildly affected areas (the parietal
lobes) showed superficial astrocytosis, affecting layers I and II of the cerebral cortex. The white
matter was well preserved with only a few foci of pallor on luxol fast blue (LFB) staining. The
thalamus showed some patchy vacuolation, neuronal loss, acute neuronal ischaemia and glio-
sis. The nuclei of the basal ganglia were unremarkable. Both hippocampi showed segmental
neuronal loss of neurons in CA1 with less severe loss in CA3 and CA4. CA2 and the dentate
gyrus were well preserved. Unequivocal granule cell dispersion was not seen. GFAP
A467T POLG-Related Mitochondrial Disease
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immunohistochemistry showed dense gliosis particularly in CA1 and to a lesser extent CA4.
The cerebellum was well preserved with a few short gaps in the Purkinje cell layer. There was a
prominent Bergman gliosis on GFAP staining. The brainstem was unremarkable.
Patient 2. A brain biopsy taken at age 6 year showed cerebral cortex and a small amount
of superficial white matter. The cortex was well populated with neurons, which showed no spe-
cific pathological abnormalities. There was some fine vacuolation of the neuropil but there
were no diagnostic features. There was a diffuse cortical astrocytosis revealed by GFAP staining
(Fig 2a and 2b).
A muscle biopsy taken at age 15 years showed a normal variation in fibre size with no excess
internal nuclei and no destructive features (no necrosis or regeneration). There was no evi-
dence of significant endomysial fibrosis. There were no ragged red fibres. There was a little
prominent lipid deposition on Oil red O. Nicotinamide adenine dinucleotide tetrazolium
reductase (NADH-TR) histochemistry showed preserved myofibre architecture. There were no
ragged blue fibres on succinate dehydrogenase (SDH) histochemistry. There were scattered
COX-negative fibres. Fibre typing was within normal limits for the site (Fig 2c–2f).
Patient 3. A deltoid muscle biopsy taken at the age of 43 years revealed mild variation in
fibre size with occasional angular atrophic fibres and several fibres with internal nuclei but no
increase in nuclear bag fibres or endomysial connective tissue. There was no evidence of
Fig 1. Liver and brain pathology for Patient 1. Post-mortem liver samples from patient 1 (a and b) showed
perivenular foci of enlarged hepatocytes with fine vacuolation (arrows). On lipid staining with oil red O (b) of
frozen sections there was diffuse lipid deposition. Sample of the cerebral cortex from the occipital lobe
showed full thickness neuronal loss with vacuolation and astrocytosis (c and d). Samples of the hippocampi
(e and f) showed segmental neuronal loss, most marked from CA1 (arrow) and gliosis in a similar pattern (f-
GFAP). Scale bars, a and b = 100 μm; c and d = 200 μm; e and f = 2 mm.
doi:10.1371/journal.pone.0145500.g001
A467T POLG-Related Mitochondrial Disease
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regeneration, necrosis or inflammation. Glycogen and lipid content was normal and fibre typ-
ing showed a normal fibre distribution. There were frequent ragged red fibres and ragged red
fibre equivalents on haematoxylin and eosin (H&E), Gomori trichrome and SDH histochemi-
cal preparations. More than 10 COX-deficient fibres were identified in the biopsy (Fig 3a–3d).
Patient 4. A deltoid muscle biopsy taken at the age of 30 years revealed mild variation in
fibre size with no significant endomysial or perimysial fibrosis, no regeneration or degenera-
tion, no vacuoles and no inflammation. Although ragged red fibres were scarce on Gomori tri-
chrome, frequent ragged blue fibres were seen on SDH histochemistry and COX-deficient
fibres were numerous (Fig 4a and 4b).
Biochemistry
Results of respiratory chain enzyme measurements in skeletal muscle are presented in Table 1.
Molecular genetics
Long-range PCR of mtDNA from patients 2, 3 and 4 revealed multiple deletions of mtDNA
(Fig 5a), whilst only a full-sized wild-type mtDNAmolecule was detected in patient 1. Southern
blot analysis demonstrated that patient 1 had depletion of mtDNA in liver (25% residual
mtDNA; Fig 5b), muscle (33% residual mtDNA; not shown) and heart (55% residual mtDNA;
not shown) but normal levels of mtDNA in the kidney (not shown). Sequencing of the POLG
Fig 2. Brain andmuscle pathology for patient 2. A brain biopsy from patient 2 showed a little neuropil
vacuolation (a) and cortical gliosis (b) but no specific diagnostic features. A muscle biopsy showed scattered
cytochrome oxidase (COX)-negative fibres (f—arrows) but no other myopathic features (c) and no ragged red
(d) or blue (e) fibres. Scale bars = 100 μm.
doi:10.1371/journal.pone.0145500.g002
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gene identified a homozygous G to A change at nucleotide position (np) 1399 in exon 7
(c.1399G>A; p.A467T) in all four individuals.
Mitochip re-sequencing analysis of the entire mtDNA molecule revealed a large number of
variants in each of the four patients (identified variants are summarised in Table 2) with con-
siderable variation between individuals. Patient 4 had an A to G point mutation at np 13528 in
the complex 1MTND5 gene which has been previously reported to be pathogenic in this
patient [16]. In addition, Patient 4 harboured an A>G change at np 12307, which has never
previously been reported and a C>T change at np 13565. The first is in theMTTL2 gene
encoding the transfer RNA for leucine (CUN), whilst the second results in a serine to phenylal-
anine substitution in the ND5 subunit of complex I. Patient 1 harboured a G>A transition at
np 14279 which results in a serine to leucine substitution in the ND6 subunit of complex I.
This has previously only been reported in 1/2704 individuals (http://www.mtdb.igp.uu.se/).
Haplotype data for each patient is presented in Table 2.
Discussion
This clinico-pathological study demonstrates the range of clinical and pathological phenotypes
that can be caused by the same homozygous mutation in a nuclear gene controlling the integ-
rity of the mitochondrial genome (Table 3). We provide extensive genetic studies to support
Fig 3. Muscle pathology for patient 3. Haematoxylin-Eosin stained section (A) showed mild variation in
fibre size and several fibres with peripheral accumulation of mitochondria (arrowhead). Gomori trichrome
preparation (B) accentuated ragged red fibres (arrowhead) and that for Succinic dehydrogenase (C) showed
many ragged blue fibres (arrowheads). COX histochemical preparation (D) revealed frequent COX-deficient
fibres (arrowheads) in keeping with mitochondrial myopathy. Scale bar = 50 μm.
doi:10.1371/journal.pone.0145500.g003
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the contention that it is likely that the mtDNA ‘phenotype’ (caused by somatic changes result-
ing from impaired mtDNAmaintenance and proofreading) determines the remarkable varia-
tion in clinical and pathological phenotypes, rather than the underlying nuclear POLG
mutation, which is identical in each of the cases presented. One extreme example of this
hypothesis is the early onset and severe disease associated with mtDNA depletion as compared
with multiple mtDNA deletions. The reason why mtDNA is depleted in some patients whereas
mtDNA deletions and somatic point mutations accumulate in others remains obscure.
Despite harbouring identical genetic mutations, all four individuals exhibited striking clini-
cal heterogeneity and confirm the extensive range of neurological involvement associated with
homozygous A467T mutations. Several points in relation to their clinical features merit com-
ment. Patient 1 was the most severely affected, with a clinical diagnosis of Alpers-Huttenlocher
syndrome. The neuropathological findings confirm those of Alpers-Huttenlocher syndrome
with the additional finding of bilateral hippocampal sclerosis (ILAE Type 1) [17]. Although
most cases of Alpers-Huttenlocher syndrome are due to compound heterozygote mutations in
POLG, our findings confirm that homozygous A467T mutations are also an important cause.
Patient 2’s presentation falls within the “MEMSA+” spectrum with an initial encephalopathic
episode followed by the subsequent development of cortical blindness, myoclonus, ataxia,
myopathy and neuropathy. However, her disease course was atypical in that following her ini-
tial presentation she remained stable, seizure-free and essentially asymptomatic (other than the
visual sequelae arising from her initial presentation) for a number of years before deteriorating
further. In addition, she also had titubation and a tremor, which are not commonly reported
with A467T mutations. Patient 3 presented with a classical picture of SANDO whilst Patient 4,
who had the mildest phenotype of these four cases, was previously diagnosed as having
“MELAS”.
Although we have assigned diagnostic labels such as “Alpers-Huttenlocher”, “MEMSA”,
“SANDO” and “MELAS-like” to emphasise the salient features of their phenotypes, it is clear
Fig 4. Muscle pathology for patient 4. Succinic dehydrogenase revealed frequent ragged blue fibres (A—red arrowheads) and there were numerous COX-
deficient fibres (B—red arrowheads) in keeping with mitochondrial myopathy. Scale bar = 50 μm.
doi:10.1371/journal.pone.0145500.g004
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that there is considerable clinical overlap between all four patients. Following a review of all
published A467T mutations in the literature, and utilising the Human DNA Polymerase γ
Database, we compiled a table of the phenotypic spectrum of homozygous A467T-related
mitochondrial disease (Table 3). Thus, our findings are in accord with the prevailing view that
the neurological features arising from the A467T mutation lie on a continuum, rather than rep-
resenting discrete and circumscribed clinical syndromes [18].
Long-range PCR analysis of mtDNA derived from the muscle tissue of all four cases demon-
strated depletion of mtDNA in patient 1 consistent with previous reports of Alpers-Huttenlo-
cher syndrome, and multiple deletions of mtDNA in patients 2, 3 and 4. The mechanism by
which genetic defects in POLG induce such changes in mtDNA is still unclear. It is likely that
recessively-inherited mutations cause disease via a loss of function effect, whilst dominantly
acting heterozygous mutations produce an inactive form of the enzyme that competes with
wild-type pol γ. As a result, mtDNA replication is impaired and error-prone, allowing
Fig 5. Long range PCR and Southern Blot analysis. A. Long PCR of muscle mt DNA from the four
patients. 1, 1kb ladder; 2,Muscle negative control; 3, Patient 2; 4, Patient 3; 5,water control; 6, Patient 4; 7,
patient 1. B. Depletion of mtDNA obtained from liver of patient 1. 1, control; 2, control; 3, patient 1.
doi:10.1371/journal.pone.0145500.g005
A467T POLG-Related Mitochondrial Disease
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Table 2. Muscle mtDNA resequencing data of the four patients.
MtDNA base position Reference sequence Patient 1 Patient 2 Patient 3 Patient 4 Amino Acid change Locus
73 A A A G G Non-coding MT-D Loop
152 T C T C C Non-coding MT-D Loop
195 T T T C C Non-coding MT-D Loop
263 A G G G G Non-coding MT-D Loop
456 C C T C C Non-coding MT-D Loop
477 T C T T T Non-coding MT-D Loop
499 G G G G A Non-coding MT-D Loop
709 G G G A G rRNA MT-RNR1
750 A G G G G rRNA MT-RNR1
1438 A G G G G rRNA MT-RNR1
1811 A A A A G rRNA MT-RNR2
1888 G G G A G rRNA MT-RNR2
2706 A A A G G rRNA MT-RNR2
3010 G A G G G rRNA MT-RNR2
3316 G G G A G Ala4Thr MT-ND1
4216 T T T C T Tyr304His MT-ND1
4336 T T C T T tRNA MT-TQ
4646 T T T T C Tyr59Tyr MT-ND2
4769 A G G G G Met100Met MT-DN2
4917 A A A G A Asn150Asp MT-DN2
5999 T T T T C Ala32Ala MT-CO1
6047 A A A A G Leu48Leu MT-CO1
7028 C C C T T Ala375Ala MT-CO1
7258 T T T C T Ile452Thr MT-CO1
7705 T T T T C Tyr40Tyr MT-CO2
8308 A A A A G tRNA MT-TK
8697 G G G A G Met57Met MT-ATP6
8860 A G G G G Thr112Ala MT-ATP6
9377 A G A A A Trp57Trp MT-CO3
9389 A A A A G Val61Val MT-CO3
10321 T T T C T Val88Ala MT-ND3
10463 T T T C T tRNA MT-TR
10819 A A A A G Lys20Lys MT-ND4
11251 A A A G A Leu164Leu MT-ND4
11332 C C C C T Ala191Ala MT-ND4
11467 A A A A G Leu236Leu MT-ND4
11719 G G G A A Gly320Gly MT-ND4
12307 A A A A G tRNA MT-TL2
12308 A A A A G tRNA MT-TL2
12372 G G G G A Leu12Leu MT-ND5
12633 C C C A C Ser99Ser MT-ND5
13203 A G A A A Ala289Ala MT-ND5
13368 G G G A G Gly344Gly MT-ND5
13528 A A A A G Thr398Ala MT-ND5
13565 C C C C T Ser410Phe MT-ND5
14279 G A G G G Ser132Leu MT-ND6
14620 C C C C T Gly18Gly MT-ND6
(Continued)
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introduction of point mutations and/or deletions of mtDNA molecules or progressive deple-
tion of mtDNA copy number [19]
Pol γ is a heterotrimer consisting of a single 140 kDa catalytic subunit, Pol-γ A, and a tight
dimer of an accessory subunit, Pol-γ B. Pol-γ A consists of three domains: an N-terminal
domain containing 3’!5’ exonuclease, a spacer domain, in which the A467T mutation is
located and a C-terminal domain, containing 5’!3’DNA polymerase activity. The accessory
subunit enhances DNA binding affinity and processivity. Chan and colleagues reported a pro-
found reduction in polymerase activity by the A467T mutant enzyme with a failure to interact
with the accessory subunit resulting in impaired DNA binding and processivity [20] [13].
However, other pathogenic mutations in the spacer region exhibited DNA-binding affinities
and processivities similar to normal controls [11] suggesting that other unknown factors
Table 2. (Continued)
MtDNA base position Reference sequence Patient 1 Patient 2 Patient 3 Patient 4 Amino Acid change Locus
14766 C C C T T Thr7Ile MT-CYB
14905 G G G A G Met53Met MT-CYB
15326 A G G G G Thr194Ala MT-CYB
15373 A A A A G Leu209Leu MT-CYB
15452 C C C A C Leu236Ile MT-CYB
15607 A A A G A Lys287Lys MT-CYB
15693 T T T T C Met316Thr MT-CYB
15758 A A A A G Ile338Val MT-CYB
15833 C C T C C Leu363Leu MT-CYB
15928 G G G A G tRNA MT-TT
16126 T T T C T Non-coding MT-DLOOP
16163 A A A G A Non-coding MT-DLOOP
16304 T T C T T Non-coding MT-DLOOP
16519 T C T C C Non-coding MT-DLOOP
doi:10.1371/journal.pone.0145500.t002
Table 3. The mitochondrial phenotypes and clinical features reported with homozygous A467Tmutations.
PHENOTYPE CLINICAL FEATURES REFERENCE
PEO Progressive external ophthalmoplegia; seizures [7]
SANDO Sensory ataxia; dysarthria; ophthalmoparesis [26]
Alpers Huttenlocher syndrome Epilepsy; EPC; psychomotor regression; liver failure; neuropathy; range of onset from 1–36 years [3, 27, 28]
Encephalopathy Encephalopathy; stroke-like episodes; myoclonus; PEO [3]
MEMSA Myopathy, epilepsy, and ataxia without ophthalmoplegia. [3]
“MNGIE-like” Gastro-intestinal dysmotility; cachexia; PEO; ptosis; peripheral neuropathy; no leukoencephalopathy;
normal plasma thymidine
[29]
Ataxia Hypotonia, Headache, muscle weakness [7]
Epilepsy Ataxia, myoclonic seizures, optic atrophy, dysarthria, and developmentally delayed [3, 7]
Epilepsy with occipital lobe
predilection
SPS; CPS; sGTCS; SE Ataxia; headache; vomiting; [30]
“Mitochondrial ataxia +”
syndrome
Ataxia; migraine-like headaches; focal epilepsy; myoclonus; PEO; neuropathy [31, 32]
Abbreviations: CPS, complex partial seizure; EPC, epilepsia partialis continua; MEMSA, Myoclonic epilepsy myopathy sensory ataxia; MINGIE,
mitochondrial neurogastrointestinal encephalopathy; PEO, progressive external ophthalmoplegia; SE, status epilepticus; sGTCS, secondary generalised
tonic-clonic seizures; SPS, simple partial seizure.
doi:10.1371/journal.pone.0145500.t003
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beyond the basic catalytic functions of Pol γ are also likely to influence the disease-causing
mechanisms. More recently, Euro and colleagues used the recently solved crystal structure of
human Pol γ [20] to analyse the structure-function relationships of various recessive mutations
associated with Alpers-Huttenlocher syndrome [21]. In addition to demonstrating reduced
DNA-binding affinity and Pol γ activity, they predicted that A467T would disrupt the hydro-
phobic structure of the spacer domain, thus impairing the function of the enzyme. The authors
postulated that, as most patients with Alpers-Huttenlocher syndrome were compound hetero-
zygotes for POLGmutations, their phenotype could be explained by the functional clusters
(designated 1 to 5) to which each mutation belonged. Moreover, A467T belonged to cluster 2
and according to their analysis, would cause Alpers-Huttenlocher syndrome if associated with
a mutation from clusters, 1, 3, 4 and 5. Thus, their model does not account for why homozy-
gous A467T mutations would result in the severe Alpers-Huttenlocher phenotype observed in
patient 1.
The interplay between mtDNA variants and mutations in nuclear genes may in part explain
the variation in mitochondrial phenotypes. To investigate this possibility further we undertook
resequencing of mtDNA using the MitoChip tool, which is able to detect levels of heteroplasmy
as low as 2% [22]. Interestingly, each of the four patients had a different mtDNA haplotype
(Table 2), raising the possibility that the mtDNA haplotype influences the POLGmutation-
related phenotype, although clearly a much larger cohort would be needed to study this in
more detail. One key question is whether the clinical heterogeneity in part arises from existing
mtDNA variation or whether misreplication from the A467T mutant enzyme results in the var-
iability in mtDNA which in turn influences the phenotype. Mitochondrial DNA resequence
analysis demonstrated a number of sites of polymorphisms in the four patients, which varied
considerably between patients. We identified a G to A mutation at np 14279 in the ND6 gene
in patient 1. Although patient 1 did not exhibit any ocular involvement, this mutation has been
previously reported in a family with Leber’s hereditary optic neuropathy [23]. However the
potential pathogenic role of this mutation remains unclear especially since the mutated residue
is not highly conserved across species.
Patient 4 harboured a number of rare variants in her mtDNA, including two missense muta-
tions: an A>G point mutation at np 13528 and a C>T change at np 13565 in the complex 1
ND5 gene, both of which have been previously reported in this patient [16]. Interestingly both
mutations have been described in haplogroup U in the absence of mitochondrial disease [24].
Although both mutations were homoplasmic or near homoplasmic in the patient’s muscle and
blood, the m.13528A>Gmutation was heteroplasmic in the patient’s asymptomatic mother
suggesting the possibility that an increase in the mutant mtDNA load in the patient may have
influenced her phenotype. However this is speculation. The contributions of both variants to
the disease phenotype remains unclear. Fibroblasts from the patient exhibited decreased mito-
chondrial membrane potential and increased lactate production, consistent with impaired
mitochondrial function. Finally, patient 4 also harboured a G>Amutation at np 12307. This
has never previously been reported in either individuals with mitochondrial disease or normal
controls according to a current review of mtDNA databases. Thus its functional role remains
uncertain. The further finding of the A467T POLGmutation in the same individual raises a
few important points. First, our findings confirm that the “MELAS” phenotype can be caused
by mutations in POLG, which is important in the differential diagnosis of this condition. Sec-
ond, the question arises as to whether patients who have previously been reported to harbour
mitochondrial diseases typically associated with mtDNA point mutations should undergo
POLG sequencing to exclude a nuclear gene defect as the cause of their phenotype [25], partic-
ularly if there is a Mendelian pattern of inheritance. Third, from a mechanistic point of view, it
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is possible that such mtDNA variations caused by defective Pol γ activity as a result of muta-
tions in POLGmay influence the overall mitochondrial phenotype.
In summary, our data provides evidence that the phenotype caused by a homozygous
nuclear gene mutation, A467T in POLG, is strongly related to the downstream mtDNA effects
in an individual patient, so that mtDNA depletion results in an early-onset severe phenotype,
whereas deletions are associated with later onset disease, and in one case fixation of a hetero-
plasmic mtDNA point mutation (arguably the result of defective Pol γ proofreading activity)
may have contributed to a MELAS-like phenotype.
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